JCR Pharmaceuticals : Notice of Organizational and Personnel Changes

News Release

April 27, 2021

JCR Pharmaceuticals Co., Ltd.

Translation

Notice of Organizational and Personnel Changes

Apr. 27, 2021 -- JCR Pharmaceuticals Co., Ltd. (TSE 4552; Chairman and President: Shin Ashida; "JCR") announced today that the following organizational and personnel changes effective from June 23, 2021.

1. Organizational Changes (Attached organizational chart)

1. Reorganization of the Corporate Planning Division and Office of the President
   The Corporate Planning Division will be abolished. The Corporate Strategy Dept., Global Business Strategy Dept., and Business Development Dept. will be established to undertake mission-critical duties according to their respective roles and will be put under the direct control of the president. Moreover, the Legal Affairs Dept. and Intellectual Property Dept., which were previously under the Corporate Planning Division, will be transferred to the Administration Division. Corporate Communications/ IR duties will be transferred to the Administration Division, and the Corporate Communications/ IR Office will be established to carry out those duties.
   Furthermore, the Office of the President will be abolished. The Secretarial Section under the Office of the President will be renamed as the Secretarial Office and will be put under the direct control of the president.
2. Reorganization of the Administration Division
   The education and training duties of the HR Development & Compliance Dept. will be transferred to the Human Resources Dept. The HR Development & Compliance Dept. will be renamed as the Internal Control Dept. and will be put under the direct control of the president. The purpose of this reorganization is to strengthen the operation of Company- wide internal control systems, including risk management duties, and the compliance- related duties that the HR Development & Compliance Dept. has previously undertaken.
   After assuming the separated education and training duties, the Human Resources Dept. will be renamed as the Human Resources Planning Dept. and will be put under the direct control of the president.
3. Reorganization of the Sales Division
   The Growth Hormone ("GH") Promotion Group in the Sales Promotion Dept. will be reestablished as an independent organization named the GH Promotion Dept. The purpose of this reorganization is to further promote the area marketing strategies tailored to each area that JCR has previously implemented with respect to Gh products, a mainstay product category.
4. Reorganization of the Research Division
   The Innovative Technology Research Institute will be established as an organization specialized in new platform technologies that will serve as the cornerstone of drug

discovery for the future.

Moreover, the Analytical R&D Center will be established. This new organization will integrate the analytical functions previously set up in the Research Division and Production Division and assume responsibility for the entire range of operations from the development of analytical methods to quality control testing in GMP* manufacturing.

*Good Manufacturing Practice

1. Reorganization of the Production Division
   To deploy the resources of the manufacturing organizations flexibly and efficiently, JCR will rename the organizations listed below as follows:
   Seishin Plant → Seishin Production Unit
   Kobe Plant → Kobe 1st Formulation Unit / Kobe 2nd Formulation Unit Murotani Plant → Murotani API Unit
   Kobe API Plant → Kobe API Unit
   Moreover, the Quality Assurance Dept. and the HQ Quality Assurance Dept. will be integrated, and quality control functions will be transferred to each unit in the Production Division and to the Analytical R&D Center under the Research Division (See (4)). Quality assurance functions will be brought under the Quality Assurance Division (See (6))
   Furthermore, the Production Planning Dept. will be abolished, and its duties will be transferred to the Production Management Dept.
2. Establishment of the Quality Assurance Division
   The Quality Assurance Division will be established to strengthen management as a new organization at the division level. The Regulatory Affairs Dept. and Pharmacovigilance Dept., which previously reported directly to the president, and the Quality Assurance Dept., which will combine the Production Division's Quality Assurance Dept. and the HQ Quality
   Assurance Dept., will be set up under the Quality Assurance Division

2. Change of Corporate Officers

In order to revise corporate officer system, senior position is abolished from this year.

Name	New Title	Current Title
	Corporate Officer	Director, Kobe Plant
Junichi Ando, Ph.D.	Executive Director, Quality
Production Division
	Assurance Division
	Corporate Officer	Senior Corporate Officer
Yutaka Honda	Executive Director,	Director, Office of the President
Administration Division (reporting	Executive Director, Corporate
	to the president)	Planning Division
	Senior Advisor, Administration	Senior Corporate Officer
Akihiro Haguchi	Executive Director,
Division
	Administration Division

3. Personnel Changes

Name	New Title	Current Title
	Director, Regulatory Affairs Dept.	Director, Regulatory Affairs Dept.
	Quality Assurance Division
	and Manager, Regulatory Affairs
Katsuya Daimon,	and Manager, Regulatory Affairs
Office
Ph.D.	Office
and Manager, Regulatory Audit
	and Manager Regulatory Audit
	Office
	Office

Name	New Title	Current Title
	Director, Pharmacovigilance	Director, Pharmacovigilance
Mariko Okada	Dept.
Dept.
	Quality Assurance Division
		Director, HQ Quality Assurance
	Director, HQ Quality Assurance	Dept.
Toshiya Tomitsuka	Dept.	and Director, Quality Assurance
	Quality Assurance Division	Dept.
		Production Division
	Senior Director, Sales Division
Hironori Yamaguchi	and Director, Sales Promotion	Senior Director, Sales Division
	Dept.
Kazuhiro Koabayashi	Director, GH Promotion Dept.	Director, Sales Promotion Dept.
Sales Division	Sales Division
		Director, Production Planning
	Senior Director, Production	Dept.
Makoto Ashida	Division	Production Division
and Corporate Strategy Dept.	and Director, Human Resources
	(Production)	Dept.
		Administration Division
Kenji Isokawa	Director, Seishin Production Unit,	Director, Seishin Plant
Production Division	Production Division
Yukihiro Kuromoto	Director, Murotani API Unit,	Director, Murotani Plant
Production Division	Production Division
Yasushi Zenitani	Director, Kobe API Unit,	Director, Kobe API Plant
Production Division	Production Division
	Scientific Expert Fellow,	Scientific Expert Fellow,
	Research Division
Kenichi Takahashi,	Research Division
and Director, Biopharmaceutical
Ph.D.	and Director, Innovative
Innovation Research Unit, Drug
	Technology Research Institute
	Discovery Research Institute
	Director, Drug Discovery
Toru Hirato, D.V.M	Research Institute	Senior Fellow, Research Division
	Research Division
	Director, CMC Development	Director, CMC Development
Kazutoshi Mihara	Research Institute
Research Institute
	and Manager, Bioprocess Unit
Yasuki Hamazume,	Director, Analytical R&D center,	Fellow, Research Division
Ph.D.	Research Division
Naoki Kawata	Director, Corporate Strategy	Director, Corporate Planning
Dept.	Division (Corporate Planning)
	Director, Global Business	Director, Corporate Planning
Masaaki Usui	Division (Product & Portfolio
Strategy Dept.
	Strategy)
	Director, Business Development	Associate Director, Corporate
Hiroshi Kagoshige	Planning Division (Business
Dept.
	Development)
Hiroyuki Fukuya	Director, Legal Affairs Dept.	Director, Legal Affairs Dept.
Administration Division	Corporate Planning Division

Name	New Title	Current Title
	Director, Intellectual Property	Director, Intellectual Property
Yoshiki Yamamoto	Dept.	Dept.
	Administration Division	Corporate Planning Division
		Senior Director, Administration
Masaki Sumiyoshi	Director, Human Resource	Division
Planning Dept.	and Director, Human Resources
		Dept.
		Director, HR Development &
Takanori Nakajima	Director, Internal Control Dept.	Compliance Dept.
		Administration Division
	Director, Accounting Department	Director, Accounting Dept.
Yoshihiro Ota	and Corporate Strategy Dept.
Administration Division
	(Finance)

About JCR Pharmaceuticals Co., Ltd.

JCR Pharmaceuticals Co., Ltd. (TSE 4552) is a global specialty pharmaceuticals company that is redefining expectations and expanding possibilities for people with rare and genetic diseases worldwide. We continue to build upon our 45-year legacy in Japan while expanding our global footprint into the US, Europe, and Latin America. We improve patients' lives by applying our scientific expertise and unique technologies to research, develop, and deliver next-generation therapies. Our approved products in Japan include therapies for the treatment of growth disorder, Fabry disease, acute graft-versus host disease, and renal anemia. Our investigational products in development worldwide are aimed at treating rare diseases including MPS I (Hurler, Hurler- Scheie and Scheie syndrome), MPS II (Hunter syndrome), Pompe disease, and more. JCR strives to expand the possibilities for patients while accelerating medical advancement at a global level. Our core values - reliability, confidence, and persistence - benefit all our stakeholders, including employees, partners, and patients. Together we soar. For more information, please visit https://www.jcrpharm.co.jp/en/site/en/.

Cautionary Statement Regarding Forward-Looking Statements

This document contains forward-looking statements that are subject to known and unknown risks and uncertainties, many of which are outside our control. Forward-looking statements often

contain words such as "believe," "estimate," "anticipate," "intend," "plan," "will," "would," "target"

and similar references to future periods. All forward-looking statements regarding our plans, outlook, strategy and future business, financial performance and financial condition are based on judgments derived from the information available to us at this time. Factors or events that could cause our actual results to be materially different from those expressed in our forward-looking statements include, but are not limited to, a deterioration of economic conditions, a change in the

legal or governmental system, a delay in launching a new product, impact on competitors' pricing

and product strategies, a decline in marketing capabilities relating to our products, manufacturing difficulties or delays, an infringement of our intellectual property rights, an adverse court decision in a significant lawsuit and regulatory actions.

This document involves information on pharmaceutical products (including those under

development). However, it is not intended for advertising or providing medical advice.

Furthermore, it is intended to provide information on our company and businesses and not to solicit investment in securities we issue.

Except as required by law, we assume no obligation to update these forward-looking statements publicly or to update the factors that could cause actual results to differ materially, even if new information becomes available in the future.

Contact:

Investors & Media:

JCR Pharmaceuticals Co., Ltd. Corporate Communications [e-mail]

###

Effective June 23, 2021

JCR Pharmaceuticals Co., Ltd. Organizational Chart

Meeting of Shareholders

Board of Directors

Chairman

President, CEO

Audit &

Supervisory

Board

Office of Audit &

Supervisory Board

Members

East Japan Sales Dept.

Tokyo Metropolitan Area Sales Dept.

Central Japan Sales Dept.

Corporate Strategy Dept.

Global Business Strategy Dept.

Business Development Dept.

International Affairs Office

HR Planning Dept.

Internal Control Dept.

Internal Audit Dept.

Administration Division

Accounting Dept.

General Affairs Dept.

Legal Affairs Dept.

Intellectual Property Dept.

Corporate Communications

/ IR Office

Tokyo Office

Information Systems Office

Secretarial Office

Business

Management Committee

							Kinki Sales Dept.
	Sales Division				West Japan Sales Dept.
							Cell Regeneration Medical Sales Dept.
							GH Promotion Dept.
							Sales Promotion Dept.
							Marketing Dept.
							Seishin Production Unit
								Kobe 1st Formulation Unit
								Kobe 2nd Formulation Unit
	Production			Murotani API Unit
	Division
			Kobe API Unit
							Production Management Dept.
							Logistics Management Dept.
							Clinical Operation Dept.
	Development
			Planning Dept.
	Division
							Data Science Dept.
	Research
			Research Management Dept.
	Division
			Innovative
			Technology
					Exploratory Research Unit
			Research
			Institute
			Drug Discovery			Pharmacology & Toxicology Unit
			Research			Regenerative Medicine Unit
			Institute
							Translational Research Unit
			CMC			Bioprocess Unit
			Development
					Formulation Research Unit
			Research
			Institute
					Cell Therapy Manufacturing Unit
			Analytical R&D				Analytical Development Unit
			Center
						QC Testing Unit
							Regulatory Affairs Dept.
	Quality
	Assurance				Pharmacovigilance Dept.
	Division
							Quality Assurance Dept.